By Amy Banks
Magstim, the pioneer of a revolutionary non-invasive treatment for depression, has announced that its latest TMS therapy product, the Horizon Performance, has achieved CE mark regulatory approval and 510(k) clearance from the FDA.
By Amy Banks
Morrisville, NC, October 17, 2017 — Magstim, a pioneer in the study and development of Transcranial Magnetic Stimulation (TMS), has received a contract from the Veterans Administration to help treat Major Depressive Disorder (MDD) in Veterans who have failed to achieve satisfactory improvement from prior antidepressant medication.
By Amy Banks
Magstim Group, Inc., the pioneer in trans-cranial magnetic stimulation and intraoperative nerve monitoring, today announced that it has appointed Lothar Krinke, Ph.D., as Chief Executive Officer effective immediately. Dr. Krinke will serve on the Board of Directors of Magstim. He will be responsible for Magstim and Technomed.